Skip to main content
Top
Published in:

Open Access 20-01-2025 | Pleural Mesothelioma | Case report

A synchronous occurrence of breast cancer and pleural mesothelioma: a case report

Authors: Zaheer Ahmad, Hashir Jehanzeb, Saad Noor Hussain, M. Umar, Humna Saleem

Published in: Journal of Medical Case Reports | Issue 1/2025

Login to get access

Abstract

Background

Malignant mesotheliomas are aggressive forms of tumors arising from mesothelial cells. The most common type is malignant pleural mesothelioma, which progresses rapidly and leads to pleural effusion. It typically affects older men and is strongly associated with asbestos exposure. However, a few studies have reported cases of malignant pleural mesothelioma resulting from non-asbestos factors, including radiotherapy for breast cancer, viruses, chronic inflammation, and BRCA1-associated protein-1-associated genetic mutations. Breast cancer is the most common sporadic cancer among women, and a small percentage of cases are related to genetic factors, such as BRCA1/2 and BRCA1-associated protein-1 mutations. While breast cancer can be linked with other primary malignancies through germline mutations, the synchronous occurrence of breast cancer with pleural mesothelioma is extremely rare.

Case presentation

We present the case of a 40-year-old Pashtun woman diagnosed with primary breast cancer. She underwent surgery followed by chemotherapy (paclitaxel). During chemotherapy, she developed right-sided chest pain and dyspnea. A computed tomography scan revealed pleural thickening, and a pleural biopsy confirmed the diagnosis of malignant pleural mesothelioma, with positive results for the diagnostic markers WT1 and D240.

Conclusion

This case represents a rare occurrence of synchronous breast cancer and pleural mesothelioma in a 40-year-old female, and is the first case reported in Khyber Pakhtunkhwa, Pakistan. These findings demonstrate the importance of comprehensive diagnostic testing and the potential role of genetic mutations in concurrent cancers. The challenge of simultaneously treating these cancers highlights the need for further research and the importance of multidisciplinary approaches.
Literature
1.
go back to reference Nuvoli B, Germoni S, Morosetti C, et al. Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. Mol Cancer. 2014;13:69.CrossRefPubMedPubMedCentral Nuvoli B, Germoni S, Morosetti C, et al. Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. Mol Cancer. 2014;13:69.CrossRefPubMedPubMedCentral
4.
go back to reference Shannon VR, Nesbitt JC, Libshitz HI. Malignant pleural mesothelioma after radiation therapy for breast cancer: a report of two additional patients. Cancer. 1995;76:437–41.CrossRefPubMed Shannon VR, Nesbitt JC, Libshitz HI. Malignant pleural mesothelioma after radiation therapy for breast cancer: a report of two additional patients. Cancer. 1995;76:437–41.CrossRefPubMed
5.
go back to reference Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL. Malignant mesothelioma and its nonasbestos causes. Arch Pathol Lab Med. 2018;142(6):753–60.CrossRefPubMed Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL. Malignant mesothelioma and its nonasbestos causes. Arch Pathol Lab Med. 2018;142(6):753–60.CrossRefPubMed
6.
go back to reference Nandikolla AG, Venugopal S, Anampa J. Breast cancer in patients with Li-Fraumeni Syndrome – a case-series study and review of literature. Breast Cancer. 2017;9:207–15.PubMedPubMedCentral Nandikolla AG, Venugopal S, Anampa J. Breast cancer in patients with Li-Fraumeni Syndrome – a case-series study and review of literature. Breast Cancer. 2017;9:207–15.PubMedPubMedCentral
7.
go back to reference Negut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer. 1997;80(5):948–50.CrossRef Negut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer. 1997;80(5):948–50.CrossRef
8.
go back to reference Cavazza A, Travis LB, Travis WD, Wolfe JT 3rd, Foo ML, Gillespie DJ, Weidner N, Colby TV. Post-Irradiation malignant mesothelioma. Cancer. 1996;77(7):1379–85.CrossRefPubMed Cavazza A, Travis LB, Travis WD, Wolfe JT 3rd, Foo ML, Gillespie DJ, Weidner N, Colby TV. Post-Irradiation malignant mesothelioma. Cancer. 1996;77(7):1379–85.CrossRefPubMed
9.
go back to reference Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45(2):116–26.CrossRefPubMed Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45(2):116–26.CrossRefPubMed
10.
go back to reference Pilarski R, Carlo MI, Cebulla C, Abdel-Rahman M. BAP1 tumor predisposition syndrome. In: GeneReviews®. Seattle: University of Washington; 1993. Pilarski R, Carlo MI, Cebulla C, Abdel-Rahman M. BAP1 tumor predisposition syndrome. In: GeneReviews®. Seattle: University of Washington; 1993.
11.
go back to reference Pan S-Y, Huang C-P, Chen W-C. Synchronous/Metachronous multiple primary malignancies: review of associated risk factors. Diagnostics. 1940;2022:12. Pan S-Y, Huang C-P, Chen W-C. Synchronous/Metachronous multiple primary malignancies: review of associated risk factors. Diagnostics. 1940;2022:12.
12.
go back to reference Deutsch M, Land SR, Begovic M, Cecchini R, Wolmark N. An association between Postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast And Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. Am J Clin Oncol. 2007;30:294–6.CrossRefPubMed Deutsch M, Land SR, Begovic M, Cecchini R, Wolmark N. An association between Postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast And Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. Am J Clin Oncol. 2007;30:294–6.CrossRefPubMed
14.
go back to reference Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304–10.CrossRefPubMedPubMedCentral Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304–10.CrossRefPubMedPubMedCentral
15.
go back to reference Vorobiof DA, Rapoport BL, Chasen MR, Abratt RP, Cronje N, Fourie L, McMichael G, Hacking D. Malignant pleural mesothelioma: a phase II trial with Docetaxel. Ann Oncol. 2002;13:412–5.CrossRefPubMed Vorobiof DA, Rapoport BL, Chasen MR, Abratt RP, Cronje N, Fourie L, McMichael G, Hacking D. Malignant pleural mesothelioma: a phase II trial with Docetaxel. Ann Oncol. 2002;13:412–5.CrossRefPubMed
16.
go back to reference Chu NQ, Liu R, Colby A, de Forcrand C, Padera RF, Grinstaff MW, Colson YL. Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts. J Thorac Cardiovasc Surg. 2020;160(3):e159–68.CrossRefPubMedPubMedCentral Chu NQ, Liu R, Colby A, de Forcrand C, Padera RF, Grinstaff MW, Colson YL. Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts. J Thorac Cardiovasc Surg. 2020;160(3):e159–68.CrossRefPubMedPubMedCentral
17.
go back to reference Prathibha S, Beckwith H, Kratzke RA, Klein M, Kne A, Tuttle TM. Synchronous breast carcinoma and peritoneal mesothelioma. Breast J. 2021;27:550–2.CrossRefPubMed Prathibha S, Beckwith H, Kratzke RA, Klein M, Kne A, Tuttle TM. Synchronous breast carcinoma and peritoneal mesothelioma. Breast J. 2021;27:550–2.CrossRefPubMed
18.
go back to reference Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M. Filippo Giancotti; New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012;18(17):4485–90.CrossRefPubMedPubMedCentral Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M. Filippo Giancotti; New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012;18(17):4485–90.CrossRefPubMedPubMedCentral
19.
go back to reference Melaiu O, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S246–52.CrossRefPubMedPubMedCentral Melaiu O, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S246–52.CrossRefPubMedPubMedCentral
Metadata
Title
A synchronous occurrence of breast cancer and pleural mesothelioma: a case report
Authors
Zaheer Ahmad
Hashir Jehanzeb
Saad Noor Hussain
M. Umar
Humna Saleem
Publication date
20-01-2025
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2025
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-024-04949-7

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video